Nitrate Vasodilator
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Nitrate Vasodilator
Nitrate Vasodilators are a class of drugs that exert their therapeutic effects by acting as nitric oxide donors. Upon administration, these compounds are metabolized to release nitric oxide (NO), a potent endogenous vasodilator. NO activates guanylate cyclase, leading to increased intracellular cyclic guanosine monophosphate (cGMP) levels. This cascade ultimately results in smooth muscle relaxation, primarily in vascular tissues, causing vasodilation. This mechanism is crucial for improving blood flow and reducing cardiac workload.
The primary approved indications for Nitrate Vasodilators revolve around cardiovascular conditions, most notably angina pectoris and coronary artery disease, where vasodilation improves oxygen supply to the myocardium and reduces preload. Some agents are also indicated for heart failure, leveraging their vasodilatory properties to reduce afterload and improve cardiac output. The first-in-class drug, nitroglycerin, was approved in 1981, with subsequent innovations focusing on improved pharmacokinetic profiles and alternative delivery methods.
The field is characterized by established therapies with long histories of use. While new molecular entities are not actively emerging, the focus remains on optimizing existing nitrate vasodilator therapies, exploring new formulations, and ensuring access to these essential medications for patients with cardiovascular and related conditions. The landscape is mature, with a strong emphasis on generic availability and established clinical practice guidelines.
11 FDA-approved Nitrate Vasodilator drugs, including BIDIL. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Nitrate Vasodilator Drugs
11 totalNitrate Vasodilator therapy has a long-standing history, originating with the approval of nitroglycerin in 1981. Early formulations paved the way for subsequent generations of nitrate vasodilators, such as isosorbide mononitrate approved in 1993, which offered improved pharmacokinetic profiles and dosing convenience. The evolution has largely focused on optimizing delivery and duration of action rather than fundamentally novel mechanisms within the class. For instance, the development of transdermal patches like NITRO-DUR and oral formulations like MONOKET aimed to provide sustained therapeutic levels, addressing the short half-life of early preparations. Individual nitrate vasodilator drugs differentiate themselves primarily through their route of administration, dosing frequency, and specific indications. Nitroglycerin, available in various forms including sublingual sprays like NITROLINGUAL PUMPSPRAY and transdermal patches like NITRO-DUR, offers rapid relief for acute angina. Isosorbide mononitrate (MONOKET) and isosorbide dinitrate provide longer-acting effects suitable for chronic angina management. BIDIL, a combination of hydralazine hydrochloride, targets heart failure, showcasing a different application of vasodilatory principles. RECTIV, a topical formulation of nitroglycerin, addresses anal fissures, highlighting a niche indication. Today, nitrate vasodilators, particularly nitroglycerin and isosorbide mononitrate, remain cornerstones in the management of angina pectoris and coronary artery disease, often used as first-line or adjunctive therapy. Their role in heart failure is more specific, with combination products like ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE being indicated for certain patient populations. The market is largely dominated by generic versions, with originator products like NITROLINGUAL PUMPSPRAY and NITRO-DUR having established significant clinical legacy. Safety profiles are well-understood, with common side effects including headache and hypotension, guiding their appropriate clinical positioning.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.